Evidence map›Paper›PMID 35251163›Full record

ReviewGastroenterology research and practice2022

Quality of Evidence Supporting the Role of Supplement Curcumin for the Treatment of Ulcerative Colitis: An Overview of Systematic Reviews.

Hongshuo Shi, Dan Wang, Wenqiang Chen, Yinghao Li, Guomin Si, Tiantian Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongshuo ShiCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.ORCID https://orcid.org/0000-0003-0012-5869
Dan WangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Wenqiang ChenCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Yinghao LiCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Guomin SiDepartment of Traditional Chinese Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Tiantian YangDepartment of Traditional Chinese Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.ORCID https://orcid.org/0000-0003-2845-5413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCurcumin is a potential complementary treatment for ulcerative colitis (UC). This overview systematically summarizes and evaluates the existing evidence of curcumin in the treatment of UC.

methodsTwo researchers searched seven databases for systematic reviews (SRs)/meta-analyses (MAs) which are about randomized controlled trials (RCTs) on curcumin for UC. Two researchers use the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the Risk of Bias in Systematic Reviews (ROBIS) scale, the list of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the included SRs/MAs.

resultsSeven published SRs/MAs were included in our study. According to the results of the AMSTAR-2 assessment, all SRs/MAs are considered to be of very low quality. According to the ROBIS evaluation results, no SR/MA has been assessed as a low risk of bias. According to the results of the PRISMA checklist assessment, no SR/MA has been fully reported on the PRISMA checklist. According to GRADE, a total of 19 outcome indicators extracted from the included SRs/MAs were evaluated. The quality of evidence was 10 moderate, 6 low, and 3 very low.

conclusionsCurcumin may be an effective and safe complementary treatment for UC. However, further standard and comprehensive SRs/MAs and RCTs are needed to provide an evidence-based medical rationale for this.

Identifiers

PMID35251163
PMCPMC8896949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.